Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2056007rdf:typepubmed:Citationlld:pubmed
pubmed-article:2056007lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:2056007lifeskim:mentionsumls-concept:C0680730lld:lifeskim
pubmed-article:2056007lifeskim:mentionsumls-concept:C1148554lld:lifeskim
pubmed-article:2056007lifeskim:mentionsumls-concept:C0008565lld:lifeskim
pubmed-article:2056007pubmed:issue2lld:pubmed
pubmed-article:2056007pubmed:dateCreated1991-8-1lld:pubmed
pubmed-article:2056007pubmed:abstractTextA high-performance liquid chromatographic assay with solid-phase extraction (SPE) for the rapid and sensitive quantitation of 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)imidazo[1, 5-a]quinoxalin-4(5H)-one (I, U-78875) in serum is described. The validation results indicated that the present method had excellent intra- and inter-assay precision (less than or equal to 9.5%, mean +/- S.D. = 3.9 +/- 3.0%, n = 25) and accuracy (less than or equal to 10.0%, mean +/- S.D. = 3.0 +/- 2.9%, n = 25), as well as improved sensitivity (2 ng ml, using a 100-microliters injection). Each chromatographic run is only 10 min and the organic solvent for the extraction of I and internal standard (U-82217) from serum was only 300 microliters. The application results obtained from the SPE method were in good agreement with the advanced automated sample preparation method.lld:pubmed
pubmed-article:2056007pubmed:languageenglld:pubmed
pubmed-article:2056007pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2056007pubmed:citationSubsetIMlld:pubmed
pubmed-article:2056007pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2056007pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2056007pubmed:statusMEDLINElld:pubmed
pubmed-article:2056007pubmed:monthFeblld:pubmed
pubmed-article:2056007pubmed:issn0021-9673lld:pubmed
pubmed-article:2056007pubmed:authorpubmed-author:ZhongW ZWZlld:pubmed
pubmed-article:2056007pubmed:issnTypePrintlld:pubmed
pubmed-article:2056007pubmed:day15lld:pubmed
pubmed-article:2056007pubmed:volume563lld:pubmed
pubmed-article:2056007pubmed:ownerNLMlld:pubmed
pubmed-article:2056007pubmed:authorsCompleteYlld:pubmed
pubmed-article:2056007pubmed:pagination427-34lld:pubmed
pubmed-article:2056007pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:2056007pubmed:meshHeadingpubmed-meshheading:2056007-...lld:pubmed
pubmed-article:2056007pubmed:meshHeadingpubmed-meshheading:2056007-...lld:pubmed
pubmed-article:2056007pubmed:meshHeadingpubmed-meshheading:2056007-...lld:pubmed
pubmed-article:2056007pubmed:meshHeadingpubmed-meshheading:2056007-...lld:pubmed
pubmed-article:2056007pubmed:meshHeadingpubmed-meshheading:2056007-...lld:pubmed
pubmed-article:2056007pubmed:year1991lld:pubmed
pubmed-article:2056007pubmed:articleTitleDetermination of 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)imidazo[1, 5-a]quinoxalin-4(5H)-one in serum by high-performance liquid chromatography.lld:pubmed
pubmed-article:2056007pubmed:affiliationDrug Metabolism Research, Upjohn Company, Kalamazoo, MI 49001.lld:pubmed
pubmed-article:2056007pubmed:publicationTypeJournal Articlelld:pubmed